Institute helps to develop game-changing Trikafta drug - Institute for Respiratory Health

Institute helps to develop game-changing Trikafta drug

Monday, March 28, 2022 | News

The Government has announced that more than 2,000 people living with cystic fibrosis will be able to access Trikafta on the pharmaceutical benefits scheme (PBS) from 1 April 2022.

This announcement is life-changing because the price of the drug was costing a completely unaffordable $250,000 but now will cost patients $42.50 per script or $6.80 for concession holders. 

The world-leading clinical trials unit run by the Institute for Respiratory Health undertook key research on the life-changing drug over the past three years in adults over the age of 18.

Siobhain Mulrennan, principal investigator on the Trikafta trial said that she was so proud of the life-transforming research that was undertaken by the Institute to get the treatment to patients sooner. 

“Trial results showed patients had an improvement in lung function, less illness and there was a better quality of life for those who participated in the trials,” said Siobhain. 

“The survival age of someone with cystic fibrosis is 53. But Trikafta is a game-changer and will help patients avoid lung transplants and help them to live longer lives. 

“This is a breakthrough treatment that will change lives for the better.” 

37-year-old Erin Hassett, who participated in the trials said she saw a difference after taking the drug within the first few weeks.

“I stopped coughing up mucus and I wasn’t as tired or out of breath as I was before.

“Without the research that the Institute undertook this drug wouldn’t be available. The drug has given me a better quality of life. I was so grateful to be a participant in the game-changing trial that took place right here in Western Australia.”

Cystic fibrosis is a genetic disease that causes persistent infections of the lung, and there is currently no cure.